



A Potential Panel of Eight-mRNA's Signature for Predicting Biochemical Recurrence-Free Survival and Disease-Free Survival in Prostate Cancer

Fanyu Peng¹, Min Wang², Hao Zhang¹, Xueyun Liu^{2*}, Yesong Guo^{1*}

¹Department of Radiation Oncology, Nanjing Medical University, Nanjing, China; ²Department of Pharmacy, Nanjing Medical University, Nanjing, China

ABSTRACT

Objective: In present study, our objective was to discover an mRNA expression signature capable of predicting the Biochemical Recurrence-free (BCR-free) survival of patients with Prostate Cancer (PCa).

Materials and methods: A cohort of 415 patients with pathologically confirmed Prostate Adenocarcinoma (PRAD) from the TCGA dataset was enrolled and analyzed. Using a specific risk score formula, the patients were categorized into high-risk or low-risk groups. Kaplan-Meier survival analyses and Cox regression analyses were conducted to assess the relationship between the mRNA signature and survival outcomes. Furthermore, the KEGG (Kyoto Encyclopedia of Genes and Genomes) analysis was employed to identify potential biological processes and signaling pathways associated with the mRNA signature. To investigate the effects of gene knockdown, CCK8 assay, and transwell assay were employed to explore changes in cell proliferation and invasion ability.

Results and discussion: Eighty-mRNAs showed significant differential expression with a logFC greater than four and a p-value less than 0.05 when comparing biochemical recurrence. Among these, eight mRNAs demonstrated a significant association with Biochemical Recurrence-free (BCR-free) survival. Utilizing a risk score based on the expression levels of these eight mRNAs, we categorized patients into low-risk and high-risk groups, revealing substantial differences in both BCR-free survival and disease-free survival between the two groups. The Oxytocin signaling pathway was involved in this mRNA signature through KEGG analysis. Additionally, cell experiments provided further evidence that the genes within this mRNA signature can influence the proliferation and invasion functions of PCa cells.

Conclusion: In this study, we have successfully developed a novel signature consisting of eight mRNAs, which is valuable in predicting survival outcomes for PCa patients. The clinical implications and underlying mechanisms of these eight mRNAs require further investigation in future studies. These findings open up promising avenues for future research that could lead to a better understanding of the biological significance and therapeutic potential of these mRNAs in PCa patients.

Keywords: mRNA signature, Prostate cancer, Biochemical recurrence, Survival

INTRODUCTION

Prostate Cancer (PCa) is the most frequently diagnosed cancer and ranks the second leading cause of cancer-related deaths in men in the USA [1]. In China, it is estimated that around 60,300 new cases of PCa and 26,600 PCa-related deaths occurred in 2015 [2]. The standard treatments for PCa include radical prostatectomy, endocrine therapy, radiotherapy, and chemotherapy. Among these, endocrine therapy has been a primary approach in PCa

treatment [3]. However, some cases of endocrine therapy-sensitive PCa may progress to Castration-Resistant Prostate Cancer (CRPC), rendering treatment more challenging and leading to a shortened median survival despite the increasing clinical use of new drugs like abiraterone and enzalutamide [4,5].

Due to the complexity and heterogeneity of PCa, accurately predicting the prognosis of individual patients remains a challenge, even with applying parameters such as TNM staging, Gleason score,

Correspondence to: Yesong Guo, Department of Radiation Oncology, Nanjing Medical University, Nanjing, China, E-mail: 1364852080gys@sina.com
Xueyun Liu, Department of Pharmacy, Nanjing Medical University, Nanjing, China, E-mail: 13512546210@163.com

Received: 05-Oct-2023, Manuscript No. JCTR-23-27321; **Editor assigned:** 09-Oct-2023, PreQC No. JCTR-23-27321(PQ); **Reviewed:** 23-Oct-2023, QC No. JCTR-23-27321; **Revised:** 30-Oct-2023, Manuscript No. JCTR-23-27321(R); **Published:** 06-Nov-2023, DOI: 0.35248/2167-0870.23.13.543.

Citation: Peng F, Wang M, Zhang H, Liu X, Guo Y (2023) A Potential Panel of Eight-mRNA's Signature for Predicting Biochemical Recurrence-Free Survival and Disease-Free Survival in Prostate Cancer. J Clin Trials. 13:543.

Copyright: © 2023 Peng F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

and PSA values [6]. Men with similar TNM stages, Gleason scores, and PSA values may experience completely different outcomes [7,8]. Therefore, there is a critical need for additional predictive tools and prognostic markers to distinguish between high-risk and low-risk individuals, enabling appropriate clinical management of PCa. Biochemical Recurrence (BCR) monitoring is also crucial in PCa treatment, as it aids in the early detection of recurrence and guides timely interventions [9].

While many studies have demonstrated the association of individual genes, both coding and non-coding RNAs, with biochemical recurrence in prostate cancer, the current research lacks a clear explanation of the underlying mechanisms driving biochemical recurrence [10,11]. Considering that biochemical recurrence is a complex pathological process, relying solely on the expression of a single gene may lead to false-positive results. Recently, identification based on microarray mRNA expression profiles has been developed and extensively used to predict various tumor features and outcomes in different cancer types. However, most studies have focused on individual genes. Our understanding of mRNA characteristics remains limited for prostate cancer, and there are no relevant studies utilizing publicly available datasets to predict biochemical recurrence-free survival. Thus, we conducted this study to delve into the available The Cancer Genomic Atlas (TCGA) dataset to determine if there exists a set of mRNAs that could distinguish between more aggressive phenotypes and poor survival outcomes in PCa patients [12]. We aimed to develop a novel mRNA signature that could significantly enhance the prediction of survival outcomes in prostate cancer patients.

MATERIALS AND METHODS

Patients and tissue samples

In this study, we utilized the mRNA expression information from the TCGA Prostate Adenocarcinoma (PRAD) RNA-sequencing database and the complete clinical dataset of TCGA PRAD up to August 11, 2016. These datasets are accessible for download on the UCSC Xena website.

To ensure the reliability and relevance of our analysis, we established specific exclusion criteria. We excluded cases that did not have a histological diagnosis of prostate adenocarcinoma acinar type (n=13 cases) and samples with clinical data but lacking Biochemical Recurrence (BCR) information (n=72 cases). Additionally, we excluded patients with missing essential clinical data, particularly the American Joint Committee on Cancer (AJCC) Tumor Stage (n=7 cases) [13]. Following applying these criteria, we included a total of 415 patients who had both mRNA expression data and corresponding clinical information in our study.

Furthermore, we retrieved mRNA expression data for 59 patients from adjacent non-tumor tissues, serving as the control group for comparative analysis. These datasets form the foundation of our study, allowing us to develop a novel mRNA signature that can effectively predict survival outcomes in prostate cancer patients.

Statistical and data mining analyses of TCGA PRAD mRNA profiles

In this study, we initially screened 27 patients who experienced biochemical relapse within two years and matched them with 140 patients who did not experience biochemical relapse beyond three years using the "matchIt" package. To ensure the two groups'

comparability, we used clinic-pathological features, including pathologic T stage, pathologic N stage, pathologic TNM stage, Gleason score [14], residual tumor, primary pattern, and PSA value, with a caliper of 0.05.

After matching, we applied the "limma" package to identify differentially expressed mRNAs based on the criteria of a Fold Change (FC) greater than $\log_2(4)$ and a p-value less than 0.05. We visualized the differentially expressed mRNAs using a heatmap generated with the "pheatmap" package.

To determine potential mRNAs associated with Biochemical Recurrence-free (BCR-free) survival, we conducted two analyses: logistic regression and single-factor Cox proportional hazards regression—the median expression of the selected mRNAs served as the cut-off point.

Next, we used the following formula to calculate the overall risk score for the final selected mRNAs: "Risk score = $\sum_{m=1}^n mRNA(m) \times coefficient(n)$ " In this formula, "m" represents the total number of genes in the panel, and "n" is the regression coefficient obtained from the multivariate Cox regression analysis for all selected mRNAs. Based on the risk score, we categorized patients into high-risk or low-risk groups, using the median as the cut-off point [15].

Using the log-rank test, we evaluated the survival distribution between these classification groups using Kaplan-Meier survival analysis and assessed the statistical significance between the stratified survival groups. Additionally, we calculated the area under the ROC curve (AUROC) to evaluate the performance of the risk score in predicting BCR-free survival [16].

All data were analyzed using R 4.2.3 packages and SPSS for Windows, version 22. A bilateral p-value of less than 0.05 was considered statistically significant.

GSEA KEGG pathway analysis settings

The utilization of Gene Set Enrichment Analysis (GSEA) involved Java software, and the gene expression file and phenotype file (high/low-risk group) were prepared following the GSEA guidelines. The parameters were set as 1000 permutations, at least 5 genes in a single pathway, and used the KEGG pathway.

Cell lines and cell culture

The C4-2 cell line, derived from the prostate, was acquired from ATCC (Manassas, VA). These cells were cultured in RPMI 1640 medium (Corning cellgro) supplemented with 10% Fetal Bovine Serum (FBS) from Thermo Fisher Scientific. All cell lines were consistently maintained at 37°C in a 5% CO₂ incubator.

Plasmids, antibodies, and reagents: The antibodies utilized in this study were procured from the following companies: Neuropeptide Y, β -Actin (Cell Signaling Technology). The vector of small hairpin RNA (shRNA) is pLKO.1, the sequence of shNPY is selected from sigma, shNPY-#1: GCGACACTACATCAACCTCAT, shNPY-#2: CAGACCTCTTGATGAGAGAAA, shNPY-#3: GTTCCCAGAA CTCGGCTTGAA.

Western blot

Cells were collected and lysed in RIPA buffer (composed of 1xPBS, 1% NP-40, 0.1% sodium dodecyl sulfate, and a protease inhibitor

cocktail from Sigma-Aldrich, St. Louis, MO) on ice for more than 15 minutes. The lysate was then centrifuged at 13,000 rpm at 4°C for 10 minutes, and the resulting supernatant was transferred to a new tube for the BCA protein quantification assay using Thermo Fisher Scientific's kit.

Next, 4X loading buffer (from Thermo Fisher Scientific) containing DTT (Dithiothreitol) was added to an equal amount of protein sample and heated at 100°C for 5 minutes. The sample was then subjected to SDS-PAGE analysis and transferred onto a nitrocellulose membrane (Thermo Fisher Scientific).

The membrane was blocked with 5% non-fat milk in 1X TBST (Tris-buffered saline with Tween 20) to prevent nonspecific binding at room temperature for 1 hour. Subsequently, the membrane was incubated with specific primary antibodies at the appropriate dilution at 4°C overnight. Afterward, the membrane was washed three times for 5 minutes each with 1X TBST and incubated with a horseradish peroxidase-conjugated secondary antibody for 1 hour at room temperature.

Finally, the immunoblots were visualized using SuperSignal West Pico Stable Peroxide Solution (Thermo Fisher Scientific).

Real-time Reverse Transcription-Polymerase Chain Reaction (RT-PCR)

Total RNA was isolated from the cells using Trizol reagent (Thermo Fisher Scientific). From 1 µg of total RNA, the first strand cDNA was synthesized using a GoScript kit (Promega). Subsequently, a two-step real-time Polymerase Chain Reaction (PCR) was carried out using SYBR Green Mix (Bio-Rad) and the C1000 Touch Thermal Cycler, CFX96 Real-Time System (Bio-Rad), following the manufacturer's protocol.

All signals were normalized against GAPDH to ensure accurate quantification, and the $2^{-\Delta\Delta C_t}$ method was applied to calculate the fold change. For the *NPY* gene, the following primer sequence was used for PCR amplification: Forward: CTGCGACACTACATCAATCTCATCA, reverse: CAGTGTCTCAGGGCTGGATCTC.

Cell viability and migration assays: Cell viability was assessed using the Cell Counting Kit-8 (CK04, DOJINDO, Kumamoto, Japan). For transwell assays, 4×10^4 to 8×10^4 cells were seeded into the upper chamber (CLS3464, Corning Costar, Corning, NY, USA) without FBS supplementation, while the lower chamber was filled with 500 µL DMEM containing 10% FBS. After 36 to 72 hours of culture, migrated cells were fixed using 4% paraformaldehyde (G1101, Servicebio, Wuhan, Hubei, China), stained with Crystal Violet Staining Solution (C0121, Beyotime, Shanghai, China), and subsequently counted under a microscope.

RESULTS

Patient characteristics

Based on pathology, all 415 patients included in our study were confirmed to have Prostate Cancer (PCa). The mean age at diagnosis was 60.88 years (standard deviation, SD=6.952), and the average follow-up period was 20.713 months (Table 1). Notably, 52 patients with adjacent non-tumor tissue were not part of our screening for differential expression of mRNAs between PCa and non-tumor tissue. Throughout the follow-up period, 36 patients

experienced biochemical recurrence.

Table 1: Clinicopathological characteristics of the patients with prostate cancer.

Characteristics	TCGA cohort (N = 415)	
	N	%
Age, median (range)	61	41-78
Biochemical recurrence		
Yes	36	8.7
No	379	91.3
pT stage		
T2		
T2a	11	2.7
T2b	10	2.4
T2c	152	36.6
T3		
T3a	131	31.6
T3b	103	24.8
T4	8	1.9
pN stage		
N0	293	70.6
N1	61	14.7
Nx	61	14.7
Gleason score		
6	42	10.1
7	214	51.6
8	52	12.5
9	104	25.1
10	3	0.7
Pathologic stage		
II	178	42.9
III	172	41.4
IV	65	15.7
Residual tumor		
R0	266	64.1
R1	119	28.7
R2	5	1.2
Rx	25	5.1
Radiation therapy		
Yes	52	12.5
No	363	87.5

Differentially expressed mRNA of PCa between patients with/without biochemical relapse

This study analyzed mRNA expression in two groups: 10 prostate cancer tissues with biochemical relapse and 10 without

biochemical relapse. Eighty differentially expressed mRNAs were identified, with a fold change greater than $\log_2(4)$ and a p-value less than 0.05. Among these 83 mRNAs, 18 (21.7%) were found to be downregulated, while the remaining 65 (78.3%) were upregulated, as summarized in Table 2.

Establishment of mRNA signatures associated with survival in PCa patients

Our study aimed to identify potential mRNA markers with prognostic significance for Biochemical Recurrence-free survival (BCR-free) in prostate cancer patients. We conducted rigorous analyses using binomial logistic regression and univariate Cox proportional hazards regression on the differentially expressed mRNAs to achieve this. From these analyses, we identified eight mRNAs that demonstrated a statistically significant association with BCR-free survival at a significance level of <0.05 . Among these mRNAs, *SCUBE2* exhibited a positive correlation with BCR-free survival, while the other seven mRNAs (*IP6K3*, *CA14*,

LIX1, *EPHA5*, *HRNBP3*, *RPE65*, and *NPY*) displayed a negative correlation, as presented in Figure 1.

By establishing the median risk score as the critical value, we successfully stratified the patients into a high-risk group of 208 patients and a low-risk group comprising 207 patients. Importantly, we observed statistically significant differences between the two groups in key clinicopathological features, such as T stage, lymph node status, pathological stage, Gleason score, and marginal distribution (Table 3). However, age at diagnosis did not significantly differ between the groups.

Additionally, we assessed the validity of the 8-mRNA signature in predicting Relapse-Free Survival (RFS) by comparing the low-risk and high-risk score groups. Our analysis demonstrated a clear and significant difference between the two groups ($P=0.001$). Furthermore, even in a multivariate Cox regression analysis, the 8-mRNA signature remained an independent prognostic factor for RFS, regardless of the Gleason score (Figure 2 and Table 4).

Table 2: The mRNA after limma package filter for $FC>4$ and $P<0.05$.

Sample ID	logFC	AveExpr	t	P.Value	adj.P.Val	B
CYP3A5	2.48239	4.569375	5.652625	1.97E-05	0.154648	2.404649
SNAP91	3.20046	6.2164	5.546416	2.48E-05	0.154648	2.229532
KNDC1	2.21337	4.242665	4.907949	0.000101	0.257873	1.139164
D4S234E	2.49082	6.24882	4.689008	0.000164	0.257873	0.751892
STXBP5L	2.41183	4.665825	4.631881	0.000187	0.257873	0.649876
DAPL1	3.60477	2.317155	4.476141	0.000265	0.257873	0.369917
PROK1	2.5193	5.14597	4.462068	0.000274	0.257873	0.344495
CCKBR	2.20471	2.114085	4.411507	0.000307	0.257873	0.253
RPE65	2.8301	2.27617	4.120485	0.000594	0.257873	-0.27784
FOXA2	2.73762	1.94139	4.045647	0.000704	0.257873	-0.41529
SMOC1	2.49096	7.92976	4.04544	0.000704	0.257873	-0.41567
DACT2	3.50009	6.851395	3.996573	0.000787	0.257873	-0.50557
CPNE6	3.28618	3.29978	3.992231	0.000794	0.257873	-0.51357
COL27A1	2.19281	6.508175	3.955879	0.000863	0.257873	-0.58052
JPH4	2.33513	7.086825	3.954687	0.000865	0.257873	-0.58272
S1PR5	2.17338	4.15609	3.795804	0.001241	0.266903	-0.87585
DMKN	2.23259	6.194565	3.71275	0.001499	0.271769	-1.02926
CA14	2.60907	3.475315	3.673135	0.00164	0.271769	-1.10244
P2RX1	2.05353	6.005505	3.669818	0.001652	0.271769	-1.10856
CYP4F8	2.89756	4.62811	3.622443	0.00184	0.274265	-1.19606
VWDE	2.21256	3.91715	3.475872	0.002563	0.280561	-1.46644
CDH22	2.05477	3.520055	3.457826	0.00267	0.280561	-1.49968
SP5	-2.10771	7.457765	-3.44124	0.002771	0.280561	-1.5302
BCL11A	2.07122	5.28653	3.349779	0.003405	0.280561	-1.69832
NLRP8	-2.22509	3.299375	-3.25975	0.004168	0.284259	-1.86324
CYP4F22	2.10217	2.948215	3.253942	0.004222	0.285428	-1.87385
C20orf56	2.98507	2.868715	3.253244	0.004229	0.285428	-1.87512
KIAA1210	2.36534	6.51733	3.202225	0.00474	0.290774	-1.96824

LAMA1	-2.21471	4.836365	-3.19839	0.004781	0.291228	-1.97522
SEMG2	3.2885	2.78095	3.19664	0.004799	0.29123	-1.97842
HRNBP3	2.65739	6.479695	3.157145	0.005241	0.304962	-2.0503
IP6K3	2.27714	4.26498	3.128646	0.005584	0.313589	-2.10206
LRAT	2.15433	3.860085	3.059019	0.006518	0.332346	-2.2281
UNC5A	-3.74871	6.844265	-3.01636	0.007163	0.338903	-2.30502
TGM3	-2.23767	7.246545	-2.99912	0.00744	0.343076	-2.33601
NTF4	2.07247	3.612355	2.994134	0.007523	0.343275	-2.34498
KCNJ3	2.35939	3.847745	2.988817	0.007611	0.343275	-2.35453
OGDHL	2.3637	5.97416	2.975557	0.007837	0.343275	-2.37832
WFDC2	2.26027	7.957015	2.97496	0.007847	0.343275	-2.37939
HNF1B	2.33896	6.18425	2.951309	0.008267	0.347773	-2.42177
NTNG1	2.48337	6.310835	2.930293	0.008657	0.353654	-2.45935
EPHA5	2.42475	4.840035	2.909116	0.009069	0.353768	-2.49714
NRCAM	-2.11698	7.44729	-2.89629	0.009327	0.353768	-2.52
CAPN9	-2.40501	4.561695	-2.80736	0.011323	0.369721	-2.6776
C1orf64	-3.98135	6.997025	-2.79735	0.011572	0.371318	-2.69524
DIO1	-2.88787	4.193225	-2.78123	0.011984	0.373552	-2.72362
TRIM29	2.24354	8.5821	2.776437	0.012109	0.373552	-2.73205
NKAIN1	2.81266	7.36192	2.74063	0.013084	0.379372	-2.79484
CEACAM20	3.33379	5.432085	2.7329	0.013304	0.38097	-2.80836
DLK2	2.04829	5.329305	2.699952	0.014283	0.386302	-2.86584
LAMB3	2.11984	8.25956	2.695571	0.014418	0.386369	-2.87346
WISP2	2.02771	5.631785	2.675632	0.015049	0.386694	-2.9081
LIX1	2.26533	3.387965	2.660976	0.015529	0.390952	-2.93351
SEMG1	2.95404	2.15583	2.637217	0.016339	0.396964	-2.97458
STAC2	2.07672	4.10782	2.629181	0.016621	0.396964	-2.98844
CST4	-2.65467	3.657695	-2.59482	0.017884	0.403036	-3.04751
GSTA3	-2.35385	1.637865	-2.58152	0.018396	0.403036	-3.07029
LOC572558	2.22935	5.288055	2.579946	0.018458	0.403036	-3.07299
LOC100190940	2.709	3.36981	2.575164	0.018646	0.404655	-3.08117
PSCA	-3.09858	11.32337	-2.55876	0.019306	0.404891	-3.10918
ZIC2	-2.50334	5.21855	-2.55035	0.019652	0.407005	-3.12351
SP8	2.0091	6.03122	2.54842	0.019733	0.407005	-3.1268
SLC6A14	-2.09713	6.402185	-2.52153	0.020885	0.408366	-3.17247
CYP26A1	-2.14378	1.87719	-2.51919	0.020989	0.408366	-3.17644
NPY	4.36698	10.05492	2.5036	0.021689	0.408366	-3.20283
LRRC7	2.11347	4.557115	2.464883	0.023524	0.420709	-3.26803
POTEH	2.00032	3.96211	2.411235	0.026308	0.434875	-3.35764
TBX10	-2.46335	3.564355	-2.40907	0.026427	0.435784	-3.36125
TRPM8	2.37912	12.6442	2.397397	0.027075	0.43764	-3.38061
SFTPA2	-2.53079	10.53594	-2.37769	0.028203	0.442484	-3.41321
TP63	2.15541	7.124175	2.374184	0.028408	0.442484	-3.419
SCUBE2	2.22925	8.863045	2.35789	0.02938	0.445468	-3.44584

FLJ26850	2.0284	4.4705	2.354599	0.02958	0.446456	-3.45125
CLSTN2	2.35366	5.86712	2.317728	0.031908	0.459234	-3.51161
LOC642587	2.2652	6.14139	2.304628	0.032776	0.461156	-3.53295
ACTC1	2.52549	7.316945	2.286287	0.034027	0.465099	-3.56272
KRT14	2.27605	7.428815	2.280263	0.034448	0.46585	-3.57247
CEACAM22P	2.25249	3.381415	2.278702	0.034557	0.465966	-3.575
CARTPT	2.16944	3.2462	2.262136	0.035742	0.472952	-3.60174
EEF1A2	-2.06218	10.10811	-2.24718	0.036844	0.479038	-3.62579
CLEC3A	2.28827	2.307475	2.215947	0.039246	0.487719	-3.67576
KRT13	2.65958	5.17372	2.187931	0.041521	0.500843	-3.72027
NEFL	2.70225	4.281065	2.126824	0.046909	0.516417	-3.81627




Figure 1: Kaplan-Meier estimates of RFS of patients with PRAD in eight genes signature.

Table 3: Correlations between risk score of eight-mRNA signature and clinicopathological characteristics.

Variable	Low-risk n (%) 207	High-risk n (%) 208	Pearson X2	P value
Age of diagnosis			0.525	0.469
≤65	150	144		
>65	57	64		
AJCC T stage			30.442	<0.001
T2	144	59		
T3+T4	93	149		
Lymphonodus status			20.743	<0.001

Negative	193	161		
Positive	14	47		
Pathological stage			37.552	<0.001
Stage II	116	62		
Stage III	76	96		
Stage IV	15	50		
Gleason Score			42.57	<0.001
<8	160	96		
≥8	47	112		
Residual Tumor			4.148	0.042
R0	141	125		
others	52	72		
Radiation therapy			14.6665	<0.001
Yes	184	160		
No	13	39		

Note: * Statistical significant results.




Table 4: Univariate and multivariate Cox regression analyses of eight-mRNA signature in the prediction of RFS.

Variable	Univariate analysis			Multivariate analysis		
	HR	95% CI	P value	HR	95% CI	P value
Risk score (high vs. low)	2.722	1.945–3.809	<0.001	2.024	1.398–2.930	<0.001
Age	1.009	1.007–1.046	0.68	0.992	0.950–1.305	0.697
T stage						
T2	As a comparison	As a comparison	0.011	As a comparison	As a comparison	0.814
T3	2.216	1.358–5.040	0.004	0.804	0.143–4.519	0.805
T4	3.824	0.849–17.224	0.081	1.301	0.150–11.290	0.811
N stage	1.777	0.915–3.452	0.089			
Pathological stage						
II	As a comparison	As a comparison	0.002	As a comparison	As a comparison	0.416
III	3.609	1.647–7.909	<0.001	2.311	0.360–14.855	0.377
IV	4.452	1.826–10.856	<0.001	1.461	0.245–8.699	0.677
Gleason Score (<8 vs. ≥8)	5.428	2.835–10.396	<0.001	2.853	1.354–6.010	<0.001
Residual Tumor (R0 vs. others)	2.688	1.524–4.472	<0.001			
Radiation Therapy	2.252	1.146–4.424	0.019			

Note: HR-hazard ratio; CI-Confidential interval; vs.- versus; *Statistical significant results.

Although the 8-mRNA-based risk score did not show a significant association with AJCC T stage in the multivariate analysis, when we stratified patients based on T stage (T0-2 vs. T3-4; Figure 3a, $P < 0.001$, unpaired t-test), we found a positive correlation with this signature. Similarly, we observed higher risk scores in the group with high Gleason scores (GS<8 vs. GS ≥ 8; Figure 3A, $P < 0.001$, unpaired t-test). Thus, we conducted a subgroup analysis to investigate the predictive value of the 8-mRNA signature across different AJCC T stages and Gleason scores (Figure 3B).

Finally, we employed the ROC package to compare the predictive accuracy of the multivariate logistic model with the 8-mRNA signature and TNM stage. Our results revealed that incorporating the 8-mRNA signature into the model led to a substantial improvement in accuracy for predicting 2-year and 5-year Overall Survival (OS) by 15.7% and 11.5%, respectively (AUROC 0.715 vs. 0.558, 0.747 vs. 0.632, Figure 4). These findings underscore the potential of the 8-mRNA signature as a valuable tool for predicting survival outcomes in prostate cancer patients.

mRNA signature-associated signaling pathways

This study utilized Gene Set Enrichment Analysis (GSEA) using the Java software from the Broad Institute to identify relevant signaling pathways and biological processes in PRAD. Figure 5 demonstrates the enrichment of specific cancer-associated pathways, including the cell cycle, NOD-like receptor signaling pathway, and Toll-like

receptor signaling pathway, in the high-risk patient group. These findings suggest a potential involvement of the 8-mRNA signature in tumor growth and immune escape in PRAD.

NPY inhibited PCa cell growth and metastasis

Based on the KEGG pathway analysis mentioned earlier, it was established that the signature is implicated in various functions, including the cell cycle. This led us to hypothesize that the genes within this signature may significantly impact the proliferation, invasion, and metastasis of Prostate Cancer (PCa) cells. As a result, we decided to focus on the *NPY* gene from the signature for further investigation.

To explore the functional role of *NPY*, we conducted experiments involving the knockdown of *NPY* expression in C4-2 cells (as depicted in Figures 6A and 6B). Subsequently, transwell experiments were performed, and the results provided evidence that *NPY* knockdown enhanced the invasive ability of C4-2 cells (Figures 6C and 6D). Moreover, we observed that *NPY* knockdown also augmented the proliferation capacity of C4-2 cells (Figure 6E).

These experimental findings support the notion that *NPY* plays a significant role in regulating the invasive and proliferative functions of C4-2 cells in prostate cancer. The results highlight the potential importance of *NPY* in the context of prostate cancer progression and suggest its possible relevance as a therapeutic target for managing the disease.




Figure 3: (A) Boxplot of risk score in patients with different T stage. (•) 2; (•) >2; (B) Boxplot of risk score in patients with different Gleason Score. (•) ≤7; (•) ≥8.




Figure 4: ROC curves of the multivariate logistic regression model with risk score of the six autophagy-related genes signature or with pathologic stage in prediction of 2-year and 5-year RFS.





Figure 5: Gene Set Enrichment Analysis (GSEA) of the 8-mRNA genes signature in TCGA dataset. Note: A) The significant 10 biological processes and signaling pathway; (B) GSEA validated enhanced activity of cell cycle.



DISCUSSION

Considering the heterogeneous nature of Prostate Cancer (PCa), achieving accurate risk assessment and effective management of patients after Radical Prostatectomy (RP) poses a significant challenge [17]. One crucial clinical issue PCa researchers face is identifying and developing reliable biomarkers that can aid in determining whether prompt adjuvant therapy is necessary following surgical or radiotherapeutic intervention [18].

The present study focused on the clinical relevance of mRNAs in prostate cancer. It investigated their involvement in complex biological functions observed in various cancer types, including Prostate Adenocarcinoma (PRAD), such as cell cycle regulation and immune responses. Specifically, we identified several mRNAs, including *IP6K3* [19,20], *HRNBP3* [21], *CA14* [22-24], *LIX1* [25,26], *RPE65* [27,28], *EPHA5* [29], *NPY* [30-33], and *SCUBE2* [34-36], which were associated with higher Gleason scores, advanced TNM staging, disease progression, metastasis, or unfavorable survival outcomes. By combining these candidate mRNAs, we improved our results' accuracy and reduced the impact of confounding factors. Recent advancements have led to the development of RNA sequencing-based signatures in various cancers, such as liver cancer, to identify subgroups exhibiting aggressive phenotypes or poor survival outcomes. Applying such signature-based approaches can enhance risk stratification and treatment decision-making in prostate cancer and other malignancies [37].

Despite the progress made in constructing mRNA signatures for cancer prognosis, many of these signatures have shown limitations in accurately reflecting clinical features and aligning with the specific needs of patients. Our study detected an mRNA signature by comparing tumor tissue with adjacent tissues in the study participants. However, this signature is needed to capture the observed clinical features fully.

To the best of our knowledge, our study is the first to reveal cases where non-Biochemical Recurrence (non-BCR) resulted in recurrence or metastasis. At the same time, patients with BCR experienced a more favorable prognosis. Within these two groups, we identified a set of 83 differentially expressed mRNAs. By analyzing RNA sequencing data from 415 prostate cancer patients, we identified an 8-mRNA signature that correlated with the AJCC T stage and predicted worse patient outcomes.

Moreover, through further multivariate analysis, we demonstrated that this 8-mRNA signature was an independent predictor of Recurrence-Free Survival (RFS) in patients with prostate cancer. These findings highlight the potential clinical significance of this signature in risk stratification and prognosis assessment, providing valuable insights into its utility as a predictive tool in the management of prostate cancer patients.

To assess the independent predictive value of the 8-mRNA signature in predicting Recurrence-Free Survival (RFS), a multivariate Cox regression analysis was conducted, taking into account various covariates, including age at diagnosis, AJCC T stage, AJCC N stage, Gleason score, and pathological stage. Univariate analysis showed that all examined covariates had a significant association with RFS. However, even after accounting for these covariates, the risk score based on the 8-mRNA signature retained its prognostic impact on RFS. Therefore, the present study concludes that the 8-mRNA signature can be an independent prognostic factor for RFS.

Furthermore, ROC analysis revealed that the 8-mRNA signature achieved an AUROC of 0.715 for predicting 2-year RFS and 0.747 for 5-year RFS. These values outperformed the level of detail provided by pathological staging alone. Pathological staging is a crucial risk assessment component associated with patient survival. Incorporating the 8-mRNA signature into risk assessment could help identify high-risk patients who might benefit from more aggressive treatment or additional adjuvant therapy. Additionally, the overexpression of *SCUBE2* correlated with lower overall survival rates. At the same time, the other seven mRNAs showed significantly higher expression in the high-risk group than in the low-risk group. The functions of these seven mRNAs in prostate cancer remain largely unexplored. Based on the pathway analysis of GSEA KEGG, we speculate that these mRNAs may be involved in cell proliferation, cell cycle regulation, and immune response, possibly influencing prostate cancer immune escape or immunotherapy effects. Cell experiments further confirmed that the genes in the signature impact prostate cancer cell proliferation and invasion functions.

It is essential to acknowledge some limitations in our study. Firstly, the mechanisms underlying the predictive value of the identified mRNAs in prostate cancer remain to be thoroughly investigated. Additionally, the specific roles of the eight mRNAs in prostate cancer phenotypes require further clarification. Moreover, while the large sample size in the published dataset supports our findings, prospective testing in clinical trials and *in vitro* and *in vivo* studies is warranted to validate and further explore these observations.

CONCLUSION

The study developed a novel mRNA signature comprising eight mRNAs, enabling the prediction of survival outcomes in prostate cancer patients. Further investigations are required to understand the clinical implications and underlying mechanisms of these mRNAs, offering potential avenues for future research. These findings hold potential for advancing our understanding of prostate cancer biology and identifying therapeutic targets for improved patient care.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

This research study utilized publicly available data from The Cancer Genome Atlas Program (TCGA). As such, no specific ethics approval or participant consent was required for this study. The data used in this research were previously collected and made available by TCGA following their own established ethical guidelines and data sharing policies.

CONSENT FOR PUBLICATION

As the data used in this study did not involve the collection or utilization of personal information or identifiable data from individuals, consent for publication was not required. The research was based on publicly available data TCGA and did not involve direct interaction or intervention with human participants.

AVAILABILITY OF DATA AND MATERIALS

All the analysis sample data in this paper come from the PRAD dataset of the TCGA database. Please refer to the Method section

for the download website.

FUNDING

The work was supported by the grants of: Jiangsu Provincial Natural Science Fund (No. BK20210977).

COMPETING INTEREST

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

AUTHORS' CONTRIBUTIONS

Fanyu Peng and Min Wang improved and refined the project details and performed the experiments; Hao Zhang provided important recommendations and all tissue specimens; Xueyun Liu and Yesong Guo designed and supervised the study; Fanyu Peng prepared all figures and all tables. All authors reviewed and approved the manuscript.

ACKNOWLEDGEMENTS

We would like to acknowledge the TCGA for providing the necessary resources, facilities, and access to data that facilitated the smooth execution of this research. Their support has been essential in ensuring the successful completion of this project.

REFERENCES

- Attard G, Parker C, Eeles RA, Schroder F, Tomlins SA, Tannock I, et al. Prostate cancer. *Lancet*. 2016; 387 (10013): 70-82.
- Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. *CA Cancer J Clin*. 2016;66(2):115-132.
- Heidenreich A, Ohlmann CH. Treatment options for hormone-refractory prostate cancer. *Urologe A*. 2005;44:1303-1314.
- Khalaf DJ, Annala M, Taavitsainen S, Finch DL, Oja C, Vergidis J, et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: A multicentre, randomised, open-label, phase 2, crossover trial. *Lancet Oncol*. 2019;20(12):1730-1739.
- Sternberg CN, Castellano D, de Bono J, Fizazi K, Tombal B, Wülfing C, et al. Efficacy and safety of cabazitaxel versus abiraterone or enzalutamide in older patients with metastatic castration-resistant prostate cancer in the CARD study. *Eur Urol*. 2021;80(4):497-506.
- Fendler WP, Weber M, Irvani A, Hofman MS, Calais J, Czernin J, et al. Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. *Clin Cancer Res*. 2019;25(24):7448-7454.
- Leidinger P, Hart M, Backes C, Rheinheimer S, Keck B, Wullich B, et al. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status. *Tumour Biol*. 2016;37:10177-10185.
- Loeb S, Sutherland DE, D'Amico AV, Roehl KA, Catalona WJ. PSA velocity is associated with Gleason score in radical prostatectomy specimen: Marker for prostate cancer aggressiveness. *Urology*. 2008;72(5):1116-1120.
- Van den Broeck T, van den Bergh RC, Briers E, Cornford P, Cumberbatch M, Tilki D, et al. Biochemical recurrence in prostate cancer: the European Association of Urology prostate cancer guidelines panel recommendations. *Eur Urol Focus*. 2020;6(2):231-234.
- Xu WH, Wang J, Sheng HY, Qu YY, Wang HK, Zhu Y, et al. Prognostic implication and functional annotations of Rad50 expression in patients with prostate cancer. *J Cell Biochem*. 2020;121(5-6):3124-3134.
- He S, Huang Z, Li X, Ding Y, Sheng H, Liu B, et al. GPM6B inhibit PCa proliferation by blocking prostate cancer cell serotonin absorptive capacity. *Dis Markers*. 2020;8810756.
- Tomczak K, Czerwińska P, Wiznerowicz M. Review The Cancer Genome Atlas (TCGA): An immeasurable source of knowledge. *Contemp Oncol*. 2015;2015(1):68-77.
- Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann Surg Oncol*. 2010;17(6):1471-1474.
- Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: Definition of grading patterns and proposal for a new grading system. *Am J Surg Pathol*. 2016;40(2):244-252.
- Sheng H, Zhang G, Huang Y, Sun L, Shi G, Ye D. A 5-LncRNA signature associated with smoking predicts the overall survival of patients with muscle-invasive bladder cancer. *Dis Markers*. 2021;2021: 8839747.
- Wang B, Wan F, Sheng H, Zhu Y, Shi G, Zhang H, et al. Identification and validation of an 18-gene signature highly-predictive of bladder cancer metastasis. *Sci Rep*. 2018;8(1):374.
- Walsh PC. Radical prostatectomy, preservation of sexual function, cancer control: The controversy. *Urol Clin North Am*. 1987;14(4):663-673.
- Held-Warmkessel J. Treatment of advanced prostate cancer. *Semin Oncol Nurs*. 2001;17:118-128.
- Dato S, Crocco P, De Rango F, Iannone F, Maletta R, Bruni AC, et al. IP6K3 and IPMK variations in LOAD and longevity: evidence for a multifaceted signalling network at the crossroad between neurodegeneration and survival. *Mech Ageing Dev*. 2021;195:111439.
- Crocco P, Saiardi A, Wilson MS, Maletta R, Bruni AC, Passarino G, et al. Contribution of polymorphic variation of inositol hexakisphosphate kinase 3 (IP6K3) gene promoter to the susceptibility to late onset Alzheimer's disease. *Biochim Biophys Acta*. 2016;1862(9):1766-1773.
- Bhat V, Srinathan S, Pasini E, Angeli M, Chen E, Baciu C, et al. Epigenetic basis of hepatocellular carcinoma: A network-based integrative meta-analysis. *World J Hepatol*. 2018;10(1):155-165.
- Zhao Y, Tao Z, Li L, Zheng J, Chen X. Predicting biochemical-recurrence-free survival using a three-metabolic-gene risk score model in prostate cancer patients. *BMC Cancer*. 2022;22(1):239.
- Liu S, Hu X, Fan X, Jin R, Yang W, Geng Y, et al. A bioinformatics research on novel mechanism of compound kushen injection for treating breast cancer by network pharmacology and molecular docking verification. *Evid Based Complement Alternat Med*. 2020;2020.
- Zhang Y, Zhang R, Liang F, Zhang L, Liang X. Identification of metabolism-associated prostate cancer subtypes and construction of a prognostic risk model. *Front Oncol*. 2020;10:598801.
- Guérin A, Martire D, Trenquier E, Lesluyes T, Sagnol S, Pratlong M, et al. LIX1 regulates YAP activity and controls gastrointestinal cancer cell plasticity. *J Cell Mol Med*. 2020;24(16):9244-9254.
- Zou J, Zhu X, Xiang D, Zhang Y, Li J, Su Z, et al. LIX1-like protein promotes liver cancer progression via miR-21-3p-mediated inhibition of fructose-1, 6-bisphosphatase. *Acta Pharm Sin B*. 2021;11(6):1578-91.
- Zhou D, Sun Y, Jia Y, Liu D, Wang J, Chen X, et al. Bioinformatics and functional analyses of key genes in smoking-associated lung adenocarcinoma. *Oncol Lett*. 2019;18(4):3613-3622.

28. Hinterhuber G, Cauza K, Dingelmaier-Hovorka R, Diem E, Horvat R, Wolff K, et al. Expression of RPE65, a putative receptor for plasma retinol-binding protein, in nonmelanocytic skin tumours. *Br J Dermatol.* 2005;153(4):785-789.
29. Li S, Zhu Y, Ma C, Qiu Z, Zhang X, Kang Z, et al. Downregulation of EphA5 by promoter methylation in human prostate cancer. *BMC Cancer.* 2015;15:18.
30. Ding Y, Lee M, Gao Y, Bu P, Coarfa C, Miles B, et al. Neuropeptide Y nerve paracrine regulation of prostate cancer oncogenesis and therapy resistance. *Prostate.* 2021;81(1):58-71.
31. Yan Y, Mao X, Zhang Q, Ye Y, Dai Y, Bao M, et al. Molecular mechanisms, immune cell infiltration, and potential drugs for prostate cancer. *Cancer Biomark.* 2021;31(1):87-96.
32. Kristensen G, Røder MA, Berg KD, Elversang J, Iglesias-Gato D, Moreira J, et al. Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer. *APMIS.* 2018;126(10):804-813.
33. Sigorski D, Wesołowski W, Gruszecka A, Gulczyński J, Zieliński P, Misiukiewicz S, et al. Neuropeptide Y and its receptors in prostate cancer: associations with cancer invasiveness and perineural spread. *J Cancer Res Clin Oncol.* 2023;149(9):5803-5822.
34. Esmaeili R, Mohammadi S, Jafarbeik-Iravani N, Yadegari F, Olfatbakhsh A, Mazaheri M, et al. Expression of SCUBE2 and BCL2 predicts favorable response in ER α positive breast cancer. *Arch Iran Med.* 2021;24(3):209-217.
35. Sheng J, Shi W, Guo H, Long W, Wang Y, Qi J, et al. The inhibitory effect of (-)-epigallocatechin-3-gallate on breast cancer progression via reducing SCUBE2 methylation and DNMT activity. *Molecules.* 2019;24(16):2899.
36. Yang B, Miao S, Li Y. SCUBE2 inhibits the proliferation, migration and invasion of human non-small cell lung cancer cells through regulation of the sonic hedgehog signalling pathway. *Gene.* 2018;672:143-149.
37. Colaprico A, Olsen C, Bailey MH, Odom GJ, Terkelsen T, Silva TC, et al. Interpreting pathways to discover cancer driver genes with Moonlight. *Nat Commun.* 2020;11(1):69.